注意缺陷多动障碍对患者生活质量的影响
- 顾静雯1,2,吴胜虎3,徐通1
作者信息
+
文章历史
+
摘要
生活质量(quality of life,QoL)是指个人在生理、心理和社会功能方面对其生活环境的主观感受,在临床工作及研究中,QoL作为评价治疗效果的目标之一,已经越来越受到重视。注意缺陷多动障碍(attention-deficit hyperactivity disorder,ADHD)是儿童期最常见的一种心理行为疾病,了解QoL对于更全面评估ADHD具有重要意义。本文介绍了ADHD患者的QoL特点及影响因素,以及各种治疗方法,尤其是药物对QoL的影响,并提出了未来ADHD QoL的研究方向。
关键词
{{custom_sec.title}}
{{custom_sec.title}}
参考文献
[1] Coghill D.The impact of medications on quality of life in Attention-Deficit Hyperactivity Disorder[J].CNS Drug,2010,24(10):843-866.
[2] Coghill D,Danckaerts M,Sonuga-Barke E,et al.Practitioner review: quality of life in child mental health-conceptual challenges and practical choices[J].J Child Psychol Psychiatry,2009,50(5):544-561.
[3] Moss MS,Hoffman CJ,Mossey J,et al.Changes over 4 years in health,quality of life,mental health,and valuation of life[J].J Aging Health,2007,19(6):1025-1044.
[4] Danckaerts M,Sonuga-Barke EJ,Banaschewski T,et al.The quality of life of children with attention deficit/hyperactivity disorder: a systematic review[J].Eur Child Adolesc Psychiatry,2010,19(2):83-105.
[5] Escobar R,Schacht A,Peter M.W,et al.Quality of life and attention-deficit/hyperactivity disorder core symptoms[J].Journal of Clinical Psychopharmacology,2010,30(2):145-151.
[6] Leo B.Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants[J/OL].Psychiatric Quarterly 2011[2011-3-25].
[7] Flapper BC,Schoemaker MM.Effect of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD[J].Develop Med Child Neurol,2008,50(4):294-299.
[8] Manos M,Frazier TW,Landgraf JM,et al.HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system[J].Curr Med Res Opin,2009,25(12):3001-10.
[9] Rothenberger A,Becker A.An observational study of once-daily modified-release methylphenidate in ADHD:quality of life,satisfaction with treatment and adherence[J].Eur Child Adolesc psychiatry,2011,20(2):257-265.
[10] Kordon A,Stollhoff K.Exploring the impact of once-daily OROS(R) methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH[J].Posgrod Med,2011,123(5):27-38.
[11] Bukstein OG,Arnold LE,Landgraf JM,et al.Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life andmedication satisfaction for children with attention-deficit/hyperactivity disorder?[J].Child Adolesc Psychiatry Ment Health,2009,3(1):39.
[12] Cheng JY,Chen RY,Ko JS,et al.Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and metaregression analysis[J].Psychopharmacology (Berl),2007,194(2):197-209.
[13] Prasad S,Harpin V,Poole L,et al.A multi-centre,randomised,open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)[J].Curr Med Res Opin,2007,23(2):379-394.
[14] Escobar R,Montoya A,Polavieja P,et al.Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol,2009,19(3):253-263.
[15] Saylor K,Williams DW,Schuh KJ,et al.Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD[J].Curr Med Res Opin,2010,26(9):2087-2095.
[16] Peter MW,Schacht A,Dittmann RW,et al.Effect of atomoxetine on quality of life and family burden: results from a randomized,placebo-controlled,double-blind studyin children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder[J].Qual Life Res,2011,20(5):691-702.
[2] Coghill D,Danckaerts M,Sonuga-Barke E,et al.Practitioner review: quality of life in child mental health-conceptual challenges and practical choices[J].J Child Psychol Psychiatry,2009,50(5):544-561.
[3] Moss MS,Hoffman CJ,Mossey J,et al.Changes over 4 years in health,quality of life,mental health,and valuation of life[J].J Aging Health,2007,19(6):1025-1044.
[4] Danckaerts M,Sonuga-Barke EJ,Banaschewski T,et al.The quality of life of children with attention deficit/hyperactivity disorder: a systematic review[J].Eur Child Adolesc Psychiatry,2010,19(2):83-105.
[5] Escobar R,Schacht A,Peter M.W,et al.Quality of life and attention-deficit/hyperactivity disorder core symptoms[J].Journal of Clinical Psychopharmacology,2010,30(2):145-151.
[6] Leo B.Improvement in global psychopathology increases quality of life during treatment of ADHD with atomoxetine or stimulants[J/OL].Psychiatric Quarterly 2011[2011-3-25].
[7] Flapper BC,Schoemaker MM.Effect of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD[J].Develop Med Child Neurol,2008,50(4):294-299.
[8] Manos M,Frazier TW,Landgraf JM,et al.HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system[J].Curr Med Res Opin,2009,25(12):3001-10.
[9] Rothenberger A,Becker A.An observational study of once-daily modified-release methylphenidate in ADHD:quality of life,satisfaction with treatment and adherence[J].Eur Child Adolesc psychiatry,2011,20(2):257-265.
[10] Kordon A,Stollhoff K.Exploring the impact of once-daily OROS(R) methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH[J].Posgrod Med,2011,123(5):27-38.
[11] Bukstein OG,Arnold LE,Landgraf JM,et al.Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life andmedication satisfaction for children with attention-deficit/hyperactivity disorder?[J].Child Adolesc Psychiatry Ment Health,2009,3(1):39.
[12] Cheng JY,Chen RY,Ko JS,et al.Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and metaregression analysis[J].Psychopharmacology (Berl),2007,194(2):197-209.
[13] Prasad S,Harpin V,Poole L,et al.A multi-centre,randomised,open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)[J].Curr Med Res Opin,2007,23(2):379-394.
[14] Escobar R,Montoya A,Polavieja P,et al.Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol,2009,19(3):253-263.
[15] Saylor K,Williams DW,Schuh KJ,et al.Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD[J].Curr Med Res Opin,2010,26(9):2087-2095.
[16] Peter MW,Schacht A,Dittmann RW,et al.Effect of atomoxetine on quality of life and family burden: results from a randomized,placebo-controlled,double-blind studyin children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder[J].Qual Life Res,2011,20(5):691-702.
-
总访问量
今日访问
在线人数
扫一扫，关注本刊微信公众号
版权所有 © 《中国儿童保健杂志》编辑部
技术支持：北京玛格泰克科技发展有限公司
技术支持：北京玛格泰克科技发展有限公司
/
| 〈 |
|
〉 |